

**S12 Table. Results of Model 5B: Fully Adjusted Model in the US Cohort**

US cohort 7,470 deaths / 14,060 patients	
Covariates	Adjusted Hazard Ratio (95% CI) for All-Cause Mortality
Age (per 1-year increase)	<b>1.03</b> (1.03 to 1.04)
Female	<b>0.89</b> (0.82 to 0.96)
Body mass index (per 1-kg/m <sup>2</sup> increase)	<b>0.99</b> (0.98 to 0.99)
Peak TR velocity (per 1-m/s increase)	<b>1.54</b> (1.46 to 1.61)
Left heart disease	<b>1.14</b> (1.07 to 1.27)
Left ventricular ejection fraction (per 1-% increase)	<b>0.99</b> (0.99 to 0.99)
Estimated glomerular filtration rate (per 1-mL/min increase)	<b>0.99</b> (0.99 to 1.00)
Race	
White	<i>Reference Group</i>
Black	<b>0.93</b> (0.85 to 1.02)
Other	<b>0.75</b> (0.67 to 0.83)
Mitral valve intervention	<b>1.14</b> (0.91 to 1.43)
Tricuspid valve intervention	<b>0.78</b> (0.31 to 1.92)
Inpatient status (vs. outpatient)	<b>1.53</b> (1.43 to 1.63)
Diabetes mellitus	<b>1.12</b> (1.06 to 1.19)
Hypertension	<b>0.80</b> (0.75 to 0.86)
Hyperlipidemia	<b>0.74</b> (0.70 to 0.78)
Smoking history	<b>1.24</b> (1.11 to 1.39)
Chronic obstructive pulmonary disease	<b>1.37</b> (1.29 to 1.45)
Chronic kidney disease	<b>1.46</b> (1.38 to 1.55)
Ischemic heart disease	<b>0.95</b> (0.89 to 1.01)
Peripheral arterial disease	<b>1.22</b> (1.13 to 1.32)
Percutaneous Coronary Intervention	<b>0.73</b> (0.66 to 0.82)
Coronary Artery Bypass Grafting	<b>0.43</b> (0.35 to 0.52)
Pacer or implantable defibrillator	<b>1.16</b> (1.06 to 1.27)
Atrial fibrillation/flutter	<b>0.97</b> (0.91 to 1.02)
Heart Failure	<b>1.31</b> (1.23 to 1.39)
Stroke or transient ischemic attack	<b>1.13</b> (1.06 to 1.21)
Dementia	<b>1.26</b> (1.19 to 1.33)
Anemia	<b>1.29</b> (1.22 to 1.36)
Cancer	<b>1.36</b> (1.28 to 1.44)
Cholesterol medications	<b>0.89</b> (0.83 to 0.96)
Antiplatelet medications	<b>0.95</b> (0.83 to 1.08)
Anticoagulants	<b>0.97</b> (0.88 to 1.07)
Beta blockers	<b>0.96</b> (0.86 to 1.07)
Renin-angiotensin-neprilysin inhibitors	<b>0.84</b> (0.78 to 0.90)
Other anti-hypertensive medications	<b>0.93</b> (0.86 to 0.99)
Diuretics	<b>1.09</b> (1.02 to 1.17)
Anti-arrhythmic medications	<b>1.13</b> (1.02 to 1.26)
Insulins	<b>1.28</b> (1.14 to 1.44)
Other anti-diabetic medications	<b>1.05</b> (0.95 to 1.16)
Nitrates	<b>1.06</b> (0.97 to 1.17)
Digoxin/digitalis	<b>1.11</b> (0.95 to 1.29)
Psychiatric treatments	<b>1.19</b> (1.11 to 1.27)

<b>Anti-inflammatories</b>	<b>0.94</b> (0.83 to 1.07)
<b>Other medications</b>	<b>1.08</b> (1.01 to 1.15)
<b><i>Aortic Stenosis Stage/Severity</i></b>	
<b>No AS</b>	<b><i>Reference Group</i></b>
<b>Mild AS</b>	<b>1.26</b> (1.16 to 1.36)
<b>Moderate AS</b>	<b>1.38</b> (1.24 to 1.53)
<b>Severe AS</b>	<b>1.36</b> (1.17 to 1.59)

Displayed are the results of model 5B which represents the fully adjusted model in the US cohort. This model is adjusted for age, sex, race, body mass index, peak tricuspid regurgitant velocity, presence of left heart disease, left ventricular ejection fraction, AS severity, estimated glomerular filtration rate, history of mitral or tricuspid valve interventions, inpatient status, diabetes, hypertension, hyperlipidemia, smoking, chronic obstructive pulmonary disease, chronic kidney disease, ischemic heart disease, peripheral arterial disease, history of percutaneous coronary intervention or coronary artery bypass grafting, pacemaker or implantable defibrillator, atrial fibrillation or flutter, heart failure, stroke or transient ischemic attack, dementia, anemia, cancer, cholesterol medications, antiplatelet medications, anticoagulants, beta blockers, renin-angiotensin-neprilysin inhibitors, other antihypertensives, diuretics, anti-arrhythmic medications, insulins, other diabetic medications, nitrates, digoxin, psychiatric medications, anti-inflammatory use, and other medications. The model included 14,060 individuals with complete profiling with 7,470 deaths and 6,590 censored individuals. All comparisons are significant at a  $p < 0.001$  level except for sex ( $p = 0.005$ ), left ventricular ejection fraction ( $p = 0.02$ ), estimated glomerular filtration rate ( $p = 0.40$ ), black race ( $p = 0.11$ ), mitral valve intervention ( $p = 0.25$ ), tricuspid valve intervention ( $p = 0.58$ ), ischemic heart disease ( $p = 0.10$ ), pacer or implantable defibrillator ( $p = 0.001$ ), atrial fibrillation/flutter ( $p = 0.23$ ), cholesterol medication ( $p = 0.002$ ), antiplatelet medications ( $p = 0.43$ ), anticoagulants ( $p = 0.56$ ), beta blockers ( $p = 0.46$ ), other anti-hypertensive medications ( $p = 0.04$ ), diuretics ( $p = 0.02$ ), anti-arrhythmic medications ( $p = 0.02$ ), other anti-diabetic medications ( $p = 0.36$ ), nitrates ( $p = 0.20$ ), digoxin/digitalis ( $p = 0.21$ ), anti-inflammatories ( $p = 0.35$ ), and other medications ( $p = 0.03$ ). TR = tricuspid regurgitant.